Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:ZSQR

Coeptis Therapeutics Q1 2026 Earnings Report

Coeptis Therapeutics logo
$10.93 +0.03 (+0.28%)
As of 06/12/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Coeptis Therapeutics EPS Results

Actual EPS
-$0.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Coeptis Therapeutics Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Coeptis Therapeutics Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Coeptis Therapeutics Earnings Headlines

Coeptis Therapeutics (NASDAQ:ZSQR) Downgraded to "Sell" Rating by Wall Street Zen
June 13 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30835916
Z Squared to Participate in Maxim Group's AI Data Center Summit
June 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/z-squared-to-participate-in-maxim-groups-ai-data-center-summit-302794415.html
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free.tc pixel
June 13 at 1:00 AM  |  Behind the Markets (Ad)
Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure Buildout
June 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/z-squared-inc-enters-50-million-committed-equity-forward-purchase-agreement-to-support-ai-infrastructure-buildout-302791528.html
Z Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® Indexes
May 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/z-squared-inc-announces-preliminary-inclusion-in-russell-3000-and-russell-2000-indexes-302782976.html
Vanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready Power
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301053/0/en/vanderbilt-report-z-squared-locks-in-zero-cash-zero-debt-path-to-42-mw-of-ai-ready-power.html
See More Coeptis Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coeptis Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coeptis Therapeutics and other key companies, straight to your email.

About Coeptis Therapeutics

Coeptis Therapeutics (NASDAQ:ZSQR), a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

View Coeptis Therapeutics Profile
Earnings Tools